Latest Rebiotix Inc. Stories
Results for groundbreaking multi-center study of lead drug candidate RBX2660 (microbiota suspension) presented at IDWeek 2014 PHILADELPHIA, Oct.
Rebiotix lead drug candidate RBX2660 (microbiota suspension) assessed in PUNCH CD study ROSEVILLE, Minn., Oct. 1, 2014 /PRNewswire/ -- Rebiotix Inc.
Rebiotix microbiota-based drug candidate used to assess a non-antibiotic approach to an urgent public health threat ROSEVILLE, Minn., Sept. 17, 2014 /PRNewswire/ -- Rebiotix Inc.
Significant company milestones include completion of the Phase 2 PUNCH(TM) CD clinical trial and FDA designation of RBX2660 as Orphan Drug and Fast Track ROSEVILLE, Minn., Aug 4, 2014
- Large; stout; burly.